Published in Arterioscler Thromb on August 14, 1991
The compliance of collagen gels regulates transforming growth factor-beta induction of alpha-smooth muscle actin in fibroblasts. Am J Pathol (1999) 2.56
Vascular smooth muscle cell hypertrophy vs. hyperplasia. Autocrine transforming growth factor-beta 1 expression determines growth response to angiotensin II. J Clin Invest (1992) 2.13
Small-diameter human vessel wall engineered from bone marrow-derived mesenchymal stem cells (hMSCs). FASEB J (2008) 1.97
VE-statin, an endothelial repressor of smooth muscle cell migration. EMBO J (2003) 1.84
Molecular regulation of contractile smooth muscle cell phenotype: implications for vascular tissue engineering. Tissue Eng Part B Rev (2010) 1.76
Genomic instability in the type II TGF-beta1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest (1997) 1.69
Rat alveolar myofibroblasts acquire alpha-smooth muscle actin expression during bleomycin-induced pulmonary fibrosis. Am J Pathol (1993) 1.44
TGFβ signaling and cardiovascular diseases. Int J Biol Sci (2012) 1.35
Transforming growth factor-beta induces airway smooth muscle hypertrophy. Am J Respir Cell Mol Biol (2005) 1.20
Decreased type II/type I TGF-beta receptor ratio in cells derived from human atherosclerotic lesions. Conversion from an antiproliferative to profibrotic response to TGF-beta1. J Clin Invest (1995) 1.18
Influence of culture medium on smooth muscle cell differentiation from human bone marrow-derived mesenchymal stem cells. Tissue Eng Part A (2009) 1.13
Suppressed smooth muscle proliferation and inflammatory cell invasion after arterial injury in elafin-overexpressing mice. J Clin Invest (2000) 1.00
Loss of microRNA-17∼92 in smooth muscle cells attenuates experimental pulmonary hypertension via induction of PDZ and LIM domain 5. Am J Respir Crit Care Med (2015) 0.93
Specific inhibition of eIF-5A and collagen hydroxylation by a single agent. Antiproliferative and fibrosuppressive effects on smooth muscle cells from human coronary arteries. J Clin Invest (1995) 0.93
Postnatal Deletion of the Type II Transforming Growth Factor-β Receptor in Smooth Muscle Cells Causes Severe Aortopathy in Mice. Arterioscler Thromb Vasc Biol (2015) 0.93
Cell biology of human vascular smooth muscle. Ann R Coll Surg Engl (1994) 0.87
TGF-β/Smad3 inhibit vascular smooth muscle cell apoptosis through an autocrine signaling mechanism involving VEGF-A. Cell Death Dis (2014) 0.86
The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype. Biomaterials (2009) 0.85
The influence of RGD-bearing hydrogels on the re-expression of contractile vascular smooth muscle cell phenotype. Biomaterials (2009) 0.83
Mitochondrial dynamics, mitophagy and cardiovascular disease. J Physiol (2016) 0.82
Overexpression of TGF-ß1 in macrophages reduces and stabilizes atherosclerotic plaques in ApoE-deficient mice. PLoS One (2012) 0.81
Edge restenosis: impact of low dose irradiation on cell proliferation and ICAM-1 expression. BMC Cardiovasc Disord (2006) 0.80
Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J (1993) 0.80
Expression of V3 Versican by Rat Arterial Smooth Muscle Cells Promotes Differentiated and Anti-inflammatory Phenotypes. J Biol Chem (2015) 0.80
Early growth response-2 expression in uterine leiomyoma cells: regulation and function. Fertil Steril (2011) 0.78
T cell-specific overexpression of TGFß1 fails to influence atherosclerosis in ApoE-deficient mice. PLoS One (2013) 0.77
In vitro evaluation of bi-layer silk fibroin scaffolds for gastrointestinal tissue engineering. J Tissue Eng (2014) 0.77
Smooth Muscle Stiffness Sensitivity is Driven by Soluble and Insoluble ECM Chemistry. Cell Mol Bioeng (2015) 0.75
Cellular Self-Assembly with Microsphere Incorporation for Growth Factor Delivery Within Engineered Vascular Tissue Rings. Tissue Eng Part A (2016) 0.75
Superparamagnetic iron oxide nanoparticles regulate smooth muscle cell phenotype. J Biomed Mater Res A (2016) 0.75